Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック